Thalidomide-O-C7-NH2 is primarily utilized in the development of targeted cancer therapies due to its ability to bind to specific proteins involved in tumor growth. It is often employed in the design of proteolysis-targeting chimeras (PROTACs), which degrade disease-causing proteins by leveraging the ubiquitin-proteasome system. This compound’s structure allows for precise modification, making it a valuable tool in creating molecules that selectively target and eliminate cancer cells while minimizing harm to healthy tissues. Additionally, it has shown potential in treating inflammatory diseases by modulating immune responses and reducing inflammation. Its applications are continually expanding as researchers explore its efficacy in other therapeutic areas, including neurodegenerative disorders and autoimmune conditions.